Chemoprophylaxis

INTERACT COALITION FORMED TO ADVANCE PATIENT ACCESS TO GENETIC TESTING FOR HEREDITARY CANCER RISK

Retrieved on: 
星期三, 四月 3, 2024
Ovarian cancer, Quest Diagnostics, Gene, Mutation, Genetic testing, Chemoprophylaxis, Incidence, Risk, Genetics, Education, SAN, Patient, Policy, Cancer, Hereditary nonpolyposis colorectal cancer, Salpingo-oophorectomy, Mastectomy, Breast cancer, Therapy, BRCA2, Physician, BRCA1, Cancer syndrome, Human, Vaccine

The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.

Key Points: 
  • The coalition seeks to provide a collective voice in support of the progression of medical professional and industry guidelines for genetic testing for inherited mutations that increase cancer risk.
  • With growing insight into the role of genetic testing in cancer risk management and treatment, the population of individuals who benefit from knowing their genetic mutation status continues to increase.
  • Hereditary cancer genetic testing has been shown to improve outcomes by identifying those most at risk and informing management strategies.
  • Among the challenges to broadening access to genetic testing for hereditary cancer risk is a time lag in updating guidelines and medical policies after the publication of new medical literature.

Mobilising Malaria Prevention: International SOS Launches Refreshed Malaria Digital Learning Solution for Global Workforces

Retrieved on: 
星期一, 十一月 20, 2023
Banking, Technology, General Health, Professional Services, Other Travel, Travel, Other Transport, Health, Transport, Other Technology, Business, Other Health, Insurance, Human Resources, Data Management, Finance, Consulting, Global health, Safety, International, Workforce, Disease, Diagnosis, Clinical governance, Digital, Knowledge, International SOS, Vaccine, Publishing, Malaria, Chemoprophylaxis

As part of an ongoing mission to support the health and wellbeing of the global workforce, International SOS , the world's leading health and security risk services company, has launched a refreshed malaria digital learning module.

Key Points: 
  • As part of an ongoing mission to support the health and wellbeing of the global workforce, International SOS , the world's leading health and security risk services company, has launched a refreshed malaria digital learning module.
  • Dr Chris Van Straten, International SOS Global Health Advisor Clinical Governance, said "International SOS has been committed to the fight against malaria for over 20 years in endemic regions, from conducting health risk assessments to implementing vector control programmes and supporting community outreach.
  • The course takes approximately 15 minutes to complete and can be easily accessed via the International SOS Training Portal within the Digital Learning Portfolios.
  • For more information on the malaria digital learning solution, please visit International SOS Digital Learning Portfolio .

Genomic Urine Test Detects Bladder Cancer from DNA Up to 12 Years Before Clinical Signs and Symptoms Appear

Retrieved on: 
星期一, 五月 1, 2023
Carcinoma, DNA, University, University of Texas Southwestern Medical Center, Urine, SBIR, Genomics, Neoplasm, AUA, University of Texas at Austin, Convergent, Cancer, American Urological Association, Quality of life, Risk assessment, Bladder cancer, Prognosis, American Cancer Society, Doctor of Philosophy, Assistant, Harvard Medical School, National Cancer Institute, MD, Patient, Small Business Innovation Research, Risk, Machine learning, Chemoprophylaxis, Annual general meeting, Cystoscopy, Somatic mutation, Diagnosis, Massachusetts General Hospital, Recurrence, Gene, Genome, Disease, Medical imaging, Vaccine, Pharmaceutical industry, Urology

CHICAGO, May 1, 2023 /PRNewswire/ -- A new genomic urine test can help doctors accurately predict bladder cancer as many as 12 years before clinical signs and symptoms emerge and long before a diagnosis can be made with cystoscopy, the most common method of detection, according to a new study* presented here at the 2023 American Urological Association (AUA) Annual Meeting.

Key Points: 
  • Developed by Convergent Genomics , the UroAmp test uses next-generation DNA sequencing and machine learning to analyze urine for mutations across 60 genes linked to bladder cancer while also measuring the entire genome.
  • "With further studies, this discovery could improve how we identify, risk stratify and monitor patients at increased risk of developing bladder cancer."
  • First, they conducted a case-control study with urine samples from 96 control subjects and 70 bladder cancer patients (22 de novo, 48 surveillance).
  • Specificity, or the percentage of people who tested negative for bladder cancer and do not have the disease, was 94%.

Panbela Announces New Research Agreement with Johns Hopkins University School of Medicine

Retrieved on: 
星期一, 四月 3, 2023
Mevalonate pathway, Therapy, Johns Hopkins School of Medicine, Cancer, Ovary, PBLA, Research, Inflammation, Patient, Chemoprophylaxis, Johns Hopkins, Pharmaceutical industry

MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine.

Key Points: 
  • MINNEAPOLIS, April 03, 2023 (GLOBE NEWSWIRE) -- Panbela Therapeutics, Inc. (Nasdaq: PBLA), a clinical stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with cancer, today announced a new research agreement with the Johns Hopkins University School of Medicine.
  • The collaboration is intended to expand the development of Panbela’s investigative agent ivospemin (SBP-101), including activity in models of ovarian and other cancer types, further evaluations into mechanism of action, and potential combination with CPP-1X and standard of care agents.
  • The research will be co-led by Robert Casero, Ph.D., professor, and Tracy Murray Stewart, Ph.D., Senior Research Scientist, both in oncology at Johns Hopkins University School of Medicine.
  • Prof. Casero and Dr. Murray Stewart are internationally recognized researchers in polyamine biology at the Johns Hopkins Kimmel Cancer Center whose research focuses on developing drugs that target critical pathways for chemotherapy and chemoprevention, including amine metabolism, epigenetic regulation, and inflammation.

CancerIQ Unveils New Service Offerings and Integrated Risk Score Calculator at NCoBC 2023

Retrieved on: 
星期五, 三月 24, 2023
High Risk, Booth, Cancer, Risk assessment, Risk, NCCN, Genetic counseling, Magnetic resonance imaging, Patient, EHR, Chemoprophylaxis, Breast MRI, HL7, Conference, Success, Medical imaging, Nursing

CHICAGO, March 24, 2023 /PRNewswire-PRWeb/ -- CancerIQ will showcase its latest precision cancer prevention and early detection offerings for breast centers at the 32nd Annual Interdisciplinary Breast Center Conference (NCoBC 2023) in Las Vegas, March 24-28, (Booth #301). The company will offer NCoBC attendees an exclusive first look at two exciting new offerings: CancerIQ Complete, the industry's first full-service suite designed to help breast centers start, run and grow high-risk breast programs; and a new real-time, EHR-initiated CancerIQ Risk Calculator.

Key Points: 
  • The company will offer NCoBC attendees an exclusive first look at two exciting new offerings: CancerIQ Complete, the industry's first full-service suite designed to help breast centers start, run and grow high-risk breast programs; and a new real-time, EHR-initiated CancerIQ Risk Calculator.
  • CancerIQ helps providers traverse the challenges of managing population-wide cancer risk assessment to offer more personalized, evidence-based care pathways that lead to early cancer detection and prevention.
  • The new Risk Score Calculator brings comprehensive risk assessment into leading EHR workflows.
  • CancerIQ is proudly sponsoring the High Risk IT Forum in the Pre-Conference High Risk Breast Program: Essentials for Success.

New Publication Highlights geneType’s Ability to Detect Breast Cancer Earlier and Provide Data for Risk Stratification

Retrieved on: 
星期四, 二月 9, 2023
Treatment, Nursing, Health, Breast cancer, Research, ASX, Genetypes, Female, Breast Cancer Research and Treatment, Data collection, IBIS, Ageing, Risk, Harvard Medical School, University, Patient, General practice, Incidence, Risk assessment, GTG, Woman, Gail, Chemoprophylaxis, Rosner, Breast, Birth control, Dietary supplement, Medical imaging, Medical device

The study results provide further clinical validation for the breast cancer risk score component of recently announced Comprehensive Breast and Ovarian HBOC Risk Test.

Key Points: 
  • The study results provide further clinical validation for the breast cancer risk score component of recently announced Comprehensive Breast and Ovarian HBOC Risk Test.
  • The study compared geneType’s simple breast cancer risk assessment against a complex model with more risk factors and two commonly used clinical models (Gail and IBIS).
  • The geneType model includes the most important risk factors for breast cancer prediction - polygenic risk score, mammographic density and family history.
  • This study highlights GTG’s epidemiological and biostatistical expertise and application of best-practices3 for integrating polygenic risk into clinical risk prediction.

DGAP-News: Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

Retrieved on: 
星期二, 八月 23, 2022
COVID-19, National Cancer Institute, United Arab Emirates, News, American Cancer Society, Pathology, Forward-looking statement, U.S. Securities and Exchange Commission, FIT, Company, Network, RNA transfection, Patient, Cancer, Ageing, Great, Death, Endoscopy, Real-time polymerase chain reaction, DNA, SEC, FDA, Chemoprophylaxis, Emirates, Biomarker, Translational research, Trial of the century, AA, Security (finance), Division, NTR, NASDAQ, Colon, Strong Memorial Hospital, Colorectal cancer, Large intestine, CRC, SEC filing, Gastroenterology, Private Securities Litigation Reform Act, Health, Review, DGAP, Neoplasm, University, MAB, Union, PCR, Intention, Form, Clinical trial, Pharmaceutical industry, Medical device, Vaccine, EU

Mainz Biomeds Medical Advisory Board to bring together a highly distinguished group of multi-disciplinary experts from across gastroenterology, clinical research and diagnostics to support its forthcoming U.S. pivotal trial for ColoAlert

Key Points: 
  • Mainz Biomeds Medical Advisory Board to bring together a highly distinguished group of multi-disciplinary experts from across gastroenterology, clinical research and diagnostics to support its forthcoming U.S. pivotal trial for ColoAlert
    BERKELEY, US MAINZ, Germany AUGUST 23, 2022 Mainz Biomed N.V. (NASDAQ:MYNZ) (Mainz Biomed or the Company), a molecular genetics diagnostic company specializing in the early detection of cancer, announced today the appointment of Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board (MAB).
  • She received her medical degree from the University of Rochester in New York and did her internal medicine residency at Strong Memorial Hospital at the University of Rochester.
  • Were thrilled to be assembling an MAB which will bring together a highly distinguished group of multi-disciplinary experts such as Dr. Turgeon, commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Mainz will continue to bring together experts in gastroenterology and pathology to provide continuing guidance as it navigates through pre-market activities including the FDA submission.

Mainz Biomed Appoints Dr. D. Kim Turgeon of University of Michigan Health to its Medical Advisory Board

Retrieved on: 
星期二, 八月 23, 2022
COVID-19, Research, National Cancer Institute, United Arab Emirates, American Cancer Society, Pathology, U.S. Securities and Exchange Commission, GLOBE, FIT, Company, Network, RNA transfection, Patient, Cancer, Ageing, Great, Death, Endoscopy, Real-time polymerase chain reaction, DNA, SEC, FDA, Chemoprophylaxis, Emirates, Biomarker, Translational research, Trial of the century, AA, Security (finance), Division, NTR, NASDAQ, Colon, Strong Memorial Hospital, Colorectal cancer, Large intestine, CRC, SEC filing, Gastroenterology, Private Securities Litigation Reform Act, Health, Review, Neoplasm, University, MAB, Union, PCR, Intention, Form, Clinical trial, Forward-looking statement, Pharmaceutical industry, Medical device, Vaccine, EU

She received her medical degree from the University of Rochester in New York and did her internal medicine residency at Strong Memorial Hospital at the University of Rochester.

Key Points: 
  • She received her medical degree from the University of Rochester in New York and did her internal medicine residency at Strong Memorial Hospital at the University of Rochester.
  • Were thrilled to be assembling an MAB which will bring together a highly distinguished group of multi-disciplinary experts such as Dr. Turgeon, commented Guido Baechler, Chief Executive Officer of Mainz Biomed.
  • Mainz will continue to bring together experts in gastroenterology and pathology to provide continuing guidance as it navigates through pre-market activities including the FDA submission.
  • ColoAlert detects colorectal cancer (CRC) via a simple-to-administer test with a sensitivity and specificity nearly as high as the invasive colonoscopy*.

DGAP-News: World Malaria Day - Vestergaard's CEO Message Advance Equity. Build Resilience. End Malaria.

Retrieved on: 
星期一, 四月 25, 2022
Family, PBO, Climate change, WHO, Incidence, Chemoprophylaxis, CSR, Patient, Population growth, Efficiency, Malaria, Mortality, Death, Mosquito, Chemistry, Vaccine, Environment, Insecticide, Africa Scout Region (World Organization of the Scout Movement), Partnership, Industry, Disease, Face, COVID, LLIN, Private sector, Agriculture, Pharmaceutical industry, Aquaculture, Renewable energy, Fine chemical, Vestergaard

#FightForWhatCounts
Lausanne, Switzerland -- (EUROPENEWSWIRE.NET) -- 25th April 2022: World Malaria Day provides us with a moment to reflect on the scale of the challenge we still face - and recognise what needs to happen to fix it.

Key Points: 
  • World Malaria Day - Vestergaard's CEO Message Advance Equity.
  • More than two thirds of those deaths were among children under the age of 5 living in the African Region.
  • So, what would I like to see happen before World Malaria Day 2023?
  • Fundamentally, that we stop managing the disease and pull together to end malaria.

World Malaria Day 2022, Vestergaard CEO: Advance Equity. Build Resilience. End Malaria.

Retrieved on: 
星期一, 四月 25, 2022
Family, PBO, Climate change, WHO, Incidence, Chemoprophylaxis, CSR, Patient, Population growth, Efficiency, Malaria, Mortality, Death, Mosquito, Chemistry, Vaccine, Environment, Insecticide, Africa Scout Region (World Organization of the Scout Movement), Partnership, Industry, Disease, Face, COVID, LLIN, Private sector, Renewable energy, Agriculture, Pharmaceutical industry, Aquaculture, Fine chemical, Vestergaard

More than two thirds of those deaths were among children under the age of 5 living in the African Region.

Key Points: 
  • More than two thirds of those deaths were among children under the age of 5 living in the African Region.
  • So, why can't we solve, rather than manage, a curable disease that we have lived with for far too long?
  • So, what would I like to see happen before World Malaria Day 2023?
  • Fundamentally, that we stop managing the disease and pull together to end malaria.